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OBJECTIVES We report on a subanalysis of the effects of losartan and atenolol on cardiovascular events in
black patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE)
study.
BACKGROUND The LIFE study compared losartan-based to atenolol-based therapy in 9,193 hypertensive
patients with left ventricular hypertrophy (LVH). Overall, the risk of the primary composite
end point (cardiovascular death, stroke, myocardial infarction) was reduced by 13% (p 
0.021) with losartan, with similar blood pressure (BP) reduction in both treatment groups.
There was a suggestion of interaction between ethnic background and treatment (p 0.057).
METHODS Exploratory analyses were performed that placed LIFE study patients into black (n  533)
and non-black (n  8,660) categories, overall, and in the U.S. (African American [n  523];
non-black [n  1,184]).
RESULTS A significant interaction existed between the dichotomized groups (black/non-black) and
treatment (p  0.005); a test for qualitative interaction was also significant (p  0.016). The
hazard ratio (losartan relative to atenolol) for the primary end point favored atenolol in black
patients (1.666 [95% confidence interval (CI) 1.043 to 2.661]; p  0.033) and favored
losartan in non-blacks (0.829 [95% CI 0.733 to 0.938]; p  0.003). In black patients, BP
reduction was similar in both groups, and regression of electrocardiographic-LVH was greater
with losartan.
CONCLUSIONS Results of the subanalysis are sufficient to generate the hypothesis that black patients with
hypertension and LVH might not respond as favorably to losartan-based treatment as
non-black patients with respect to cardiovascular outcomes, and do not support a recom-
mendation for losartan as a first-line treatment for this purpose. The subanalysis is limited by
the relatively small number of events. (J Am Coll Cardiol 2004;43:1047–55) © 2004 by the
American College of Cardiology Foundationc
m
1
p
a
p
w
o
w
n
o
a
s
i
i
i
e
3he recently published Losartan Intervention For Endpoint
eduction in hypertension (LIFE) study (1) was the first to
emonstrate, in a head-to-head comparison of two antihy-
ertensive agents, that a “new generation” antihypertensive
gent (losartan) offers better cardiovascular protection than
herapy with a traditional agent (atenolol), despite compa-
able blood pressure (BP) reduction. In the overall LIFE
tudy, the risk of the occurrence of the primary composite
From the *Department of Internal Medicine, Division of Hypertension, University
f Michigan, Ann Arbor, Michigan; †Albert Einstein College of Medicine, Bronx,
ew York; ‡City Hospital, Birmingham, England; §Department of Medicine,
ahlgrenska University Hospital, O¨stra, Go¨teborg, Sweden; Division of Cardiology,
ornell Medical Center, New York, New York; ¶Case Western Reserve University,
ivision of Hypertension, Cleveland, Ohio; #Merck & Co., Inc., West Point,
ennsylvania; **Department of Internal Medicine, University of Michigan, Ann
rbor, Michigan, and Department of Cardiology, Ullevaal University Hospital, Oslo,
orway; ††Department of Internal Medicine, Division of Hypertension, University
f Texas Southwestern, Dallas, Texas; and the ‡‡Howard University Hospital,
eneral Clinical Research Center, Washington, DC. This investigator-initiated
tudy was supported by Merck & Co., Inc.
Manuscript received June 6, 2003; revised manuscript received October 10, 2003,rccepted November 3, 2003.ardiovascular end point (cardiovascular death, stroke, and
yocardial infarction [MI]) was significantly reduced by
3% (p 0.021) with losartan (compared to atenolol) in the
rimary analysis, which adjusted for Framingham risk score
nd the degree of electrocardiographic-left ventricular hy-
ertrophy (ECG-LVH) at baseline (unadjusted reduction
ith losartan was 15%; p 0.009). Among the components
f the primary composite end point, losartan was associated
ith a significant reduction in the risk of stroke (fatal and
onfatal) by 25% (p  0.001). Treatment differences in
ther components of the primary composite end point (fatal
nd nonfatal MI and cardiovascular mortality) were not
ignificant in the main study. In addition, patients random-
zed to losartan experienced a significantly greater reduction
n LVH, as assessed by ECG. Reduction of BP was similar
n the treatment groups. At the last visit before a primary
nd point or end of follow-up, systolic BP was reduced by
0.2 and 29.1 mm Hg in the losartan and atenolol groups,
espectively (p  0.015); diastolic BP was reduced by 16.6
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espectively (p  NS).
Patients with diabetes (n  1,195) and those with
solated systolic hypertension (ISH) (n  1,326) at baseline
ere prespecified to be of special interest in the LIFE study.
ubgroup analyses in these patients found losartan was
ssociated with a 25% reduction in the risk of the primary
omposite end point compared with atenolol in both groups
p  0.031 for diabetics [2] and p  0.059 in patients with
SH [3]). In addition, the LIFE study analysis plan pre-
efined analyses of the primary composite end point in 23
emographic, geographic, disease-history, and disease-
everity subgroups. Although no significant interactions
ccurred between treatment and any of the predefined
ubgroups, there was a suggestion of interaction between
thnic background and treatment (p 0.057). This analysis
as based on the five ethnic groups reported by the
nvestigators, some of which included small sample sizes;
herefore, further exploratory analyses were subsequently
erformed to investigate this finding. Results of these
nalyses are presented here.
ETHODS
he complete LIFE study protocol (4), patient baseline
haracteristics (5), primary study results (1), and results in
atients with diabetes (2) and ISH (3) have been published.
articipants and procedures. Patients age 55 to 80 years
ith previously treated or untreated hypertension (n 
,193), ECG signs of LVH (by Cornell voltage-duration
roduct or Sokolow-Lyon voltage criteria), and sitting BP
after one to two weeks on placebo) of 160 to 200 mm Hg
ystolic and/or 95 to 115 mm Hg diastolic, were random-
zed either to losartan-based or atenolol-based treatment at
ore than 900 centers in seven countries (Denmark, Fin-
and, Iceland, Norway, Sweden, United Kingdom, U.S.).
tudy therapy was initiated with 50 mg of blinded losartan
r atenolol and the matching placebo of the other agent.
tudy drug dosage was increased, if necessary, to achieve
arget BP (140/90 mm Hg) by the addition of hydrochlo-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ALLHAT  Antihypertensive therapy and Lipid
Lowering Heart Attack prevention Trial
BP  blood pressure
CHD  coronary heart disease
CI  confidence interval
ECG  electrocardiogram/electrocardiographic
ISH  isolated systolic hypertension
LIFE  Losartan Intervention For Endpoint
reduction in hypertension study
LVH  left ventricular hypertrophy
MI  myocardial infarction
SOLVD  Studies Of Left Ventricular Dysfunction
VA  Veterans Administrationothiazide 12.5 mg, followed by an increase of blinded [edication to 100 mg and subsequent increase of hydro-
hlorothiazide or addition of other medication, with the
xception of angiotensin II antagonists, angiotensin-
onverting enzyme (ACE) inhibitors, or beta-blockers. All
atients were to be followed for at least four years and until
t least 1,040 patients experienced a primary cardiovascular
nd point (cardiovascular mortality, stroke, or MI). The
tudy ran its full course, and at termination of the study
September 16, 2001, as determined by the LIFE Steering
ommittee) 1,096 patients had experienced a primary event
hat was confirmed by the Endpoint Classification Com-
ittee; mean duration of follow-up was 4.8 years.
tatistical methods. As previously described (4), the sta-
istical significance of the effect of losartan compared with
tenolol on the primary composite end point was assessed by
Cox regression model that included the baseline variables
f the Framingham risk score and ECG measures of LVH.
he effect of losartan versus atenolol treatment among
ubgroups (treatment-by-factor interactions) was also ana-
yzed; ethnic group was included as a predefined subgroup
ecause data were intended to be submitted to regulatory
gencies. A set of indicator variables was defined for each
actor, which was included in the Cox regression analyses
ith the treatment indicator and the products of the
reatment indicator with each of the subgroup factor indi-
ators. Factors considered for subgroup analysis of the
rimary composite end point are listed in Table 1. Under
he prespecified analysis plan, significant interactions were
o be further examined to determine whether the interaction
as qualitative or quantitative (6).
Differences between the treatment groups with respect to
ean changes in BP and ECG measures of LVH from
aseline were assessed with a rank-transformed analysis-of-
ariance model. Note that there were no formal adjustments
or multiplicity.
ESULTS
orldwide subgroup analyses. As described in the pre-
ious text, the statistical significance of the differing effect
f losartan compared with atenolol on the primary
omposite end point was analyzed. No significant inter-
ctions were seen between treatment and any of the
redefined subgroups (Table 1); however, there was a
uggestion of interaction between ethnic background and
reatment (p  0.057). The prespecified test for interac-
ion between ethnic background and treatment was based
n a comparison of the effect of losartan among the five
ifferent ethnic background categories reported by the
nvestigators: white (n  8,503), black (n  533),
ispanic (n  100), Asian (n  43), and other (n  14).
rimary composite end point results for the prespecified
thnic groups are shown in Figure 1 (ethnic group
dentified as “other” [n  14] is not shown). White
atients had lower risk with losartan (hazard ratio: 0.819
95% confidence interval (CI) 0.724 to 0.928]), whereas
b
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hazard ratio: 1.598 [95% CI 1.004 to 2.543]). Because
he data for all but the white and black groups were
imited, a further exploratory analysis was performed that
ivided patients into black (n  533) and non-black
roups (n  8,660). This analysis yielded a statistically
ignificant interaction (p  0.005). Further, a test for
ualitative interaction (i.e., effect of losartan differs in
irection between blacks and non-blacks, not just in
agnitude) was also statistically significant (p  0.016).
The hazard ratio adjusted for baseline Framingham risk
able 1. Results of Test for Interaction Between Baseline
ubgroup and Treatment for the Primary End Point
Subgroup
Test for Interaction
(p Value)
emographics
Age 0.185
Gender 0.420
Country 0.607
Ethnic group 0.057
isease history
MI 0.316
Stroke 0.211
IHD 0.209
Angina 0.250
Heart failure 0.733
Diabetes 0.170
Microalbuminuria 0.383
ISH 0.176
linical characteristics
Smoking status 0.282
Alcohol intake 0.420
Exercise status 0.892
BMI 0.290
Systolic BP 0.725
Diastolic BP 0.402
Total cholesterol 0.975
HDL cholesterol 0.114
ECG-LVH (Cornell) 0.485
ECG-LVH (Sokolow-Lyon) 0.422
Framingham risk score 0.922
MI  body mass index; BP  blood pressure; ECG  electrocardiogram; HDL 
igh-density lipoprotein; IHD  ischemic heart disease; ISH  isolated systolic
ypertension; LVH  left ventricular hypertrophy; MI  myocardial infarction.
igure 1. Results of primary composite end point by ethnic group. The
ots represent the hazard ratio; dot size is proportional to the number of
atients for each ethnic group, as shown to the left. The line through eachcot corresponds to the 95% confidence interval.core and degree of LVH for the primary composite end
oint favored atenolol in black patients and favored losartan
n non-black patients; similar results were found for the
econdary component end points (Table 2A).
.S. Almost all black patients were enrolled in the U.S.
523 of 533 black patients). It is important to note that
ifferences existed between the baseline characteristics of
atients enrolled in the U.S. relative to the overall study
opulation (Table 3). The overall rate of occurrence of
rimary end points in the U.S. was also higher than in other
ountries (U.S. primary composite event rate per 1,000 years
f patient follow-up was 30.6 and 32.1 for the losartan and
tenolol groups, respectively, versus 22.4 and 27.0 for the
on-U.S. losartan and atenolol groups, respectively). There-
ore, to avoid the confounding effects of region, further
nalyses to explore the apparent differences in response in
lack and non-black patients compared African-American
n  523) and non-black (n  1,184) patients within the
.S.
The primary end point results in the African-American
nd non-black U.S. population were similar to those found
n the overall population; results for the secondary compo-
ent end points also trended similarly (Table 2B).
Figure 2 shows the Kaplan-Meier curves for the primary
omposite end point in the African-American and non-
lack U.S. patients. The trend for atenolol in African
mericans appears to differ during the first two years
ompared to later. In the first two years of the study, the
rimary composite end point crude incidence rates in
frican Americans were similar in each treatment group
two-year crude composite end point rate: 8.6% and 6.4% in
he losartan and atenolol groups, respectively) but, thereaf-
er, the incidence of new events on atenolol appears to
ecline (four-year crude composite end point rate: 15.3%
nd 9.7% in the losartan and atenolol groups, respectively).
The baseline characteristics of African-American and
on-black U.S. patients are shown in Table 3. A number of
ifferences existed between African Americans and non-
lack U.S. patients. For example, at baseline, African
mericans were younger and were more likely to have
iabetes, a history of cerebrovascular disease, or to be
mokers. African Americans had higher baseline serum
reatinine, serum uric acid, and urine albumin levels and
ere more likely to have received prior treatment with
alcium channel blockers or diuretics. African Americans
ad a lower Framingham risk score; they were less likely to
e female, likely to have a history of coronary heart disease,
nd to have been treated with a beta-blocker or renin-
ngiotensin system inhibiting agent.
However, as depicted in Figure 3, the difference in the
rimary end point rate between African Americans and
on-black U.S. patients was unaffected by adjustment for
arious baseline factors.
The BP response in African Americans showed results
imilar to the overall LIFE study. Similar reductions oc-
urred in both treatment groups in African-American pa-
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Risk Reduction in Hypertensive Black Patients March 17, 2004:1047–55ients (Fig. 4). In African Americans, sitting systolic BP at
he last visit before a primary end point occurred, or at end
f follow-up, decreased by 30.3 and 29.1 mm Hg to 141.7
nd 142.7 mm Hg in the losartan and atenolol groups,
able 2. Primary Composite and Secondary Component End Po
A: Worldwide Black
Worldwide
Crude Rate
Losartan (n  270)
Rate‡ N (%) Rat
omposite 41.8 46 (17.0) 25
Components of Primary Composi
ardiovascular mortality 19.1 22 (8.1) 13
I (fatal/nonfatal) 11.8 13 (4.8) 5
troke (fatal/nonfatal) 21.9 24 (8.9) 11
Worldwide N
Crude Rate
Losartan (n  4,355) A
Rate‡ N (%) Rat
omposite 22.8 462 (10.7) 28
Components of Primary Composi
ardiovascular mortality 8.7 182 (4.2) 10
I (fatal/nonfatal) 9.0 185 (4.3) 8
troke (fatal/nonfatal) 10.2 208 (4.8) 14
B: U.S. Black an
U.S. Bl
Crude Rate
Losartan (n  264)
Rate‡ N (%) Ra
omposite 42.7 46 (17.4) 26
Components of Primary Composi
ardiovascular mortality 19.5 22 (8.3) 13
I (fatal/nonfatal) 12.0 13 (4.9) 5
troke (fatal/nonfatal) 22.4 24 (9.1) 11
U.S. Non-
Crude Rate
Losartan (n  605)
Rate‡ N (%) Ra
omposite 25.6 68 (11.2) 34
Components of Primary Composi
ardiovascular mortality 11.2 31 (5.1) 16
I (fatal/nonfatal) 11.0 29 (4.8) 11
troke (fatal/nonfatal) 11.3 30 (5.0) 16
p values 0.05. †p values 0.01. ‡Per 1,000 patient-years of follow-up. §Baselin
ramingham risk score are included in Cox proportional hazard model as covariates. 
o atenolol are based on the Cox proportional hazard model.
CI  confidence interval; MI  myocardial infarction.espectively. Sitting diastolic BP in African Americans lecreased by 17.3 and 17.2 mm Hg to 80.6 and 80.5 mm
g in the losartan and atenolol groups, respectively. In
on-black U.S. patients, sitting systolic BP decreased by
1.1 and 30.3 mm Hg to 140.4 and 140.3 mm Hg in the
n Black and Non-Black Patients
Non-Black Patients
k Patients
Adjusted Hazard Ratio§
(95% CI) p Value
lol (n  263)
N (%)
29 (11.0) 1.666 (1.043–2.661) 0.033*
d Point—Secondary End Points
15 (5.7) 1.483 (0.764–2.879) 0.244
6 (2.3) 2.074 (0.786–5.473) 0.141
12 (4.6) 2.179 (1.079–4.401) 0.030*
lack Patients
lol (n  4,325)
Adjusted Hazard Ratio§
N (%) (95% CI) p Value
559 (12.9) 0.829 (0.733–0.938) 0.003†
d Point—Secondary End Points
219 (5.1) 0.842 (0.692–1.025) 0.087
182 (4.2) 1.036 (0.844–1.271) 0.735
297 (6.9) 0.700 (0.586–0.836) 0.001†
-Black Patients
atients
lol (n  259)
Adjusted Hazard Ratio‡
N (%) (95% CI) p Value
29 (11.2) 1.665 (1.042–2.659) 0.033*
d Point—Secondary End Points
15 (5.8) 1.480 (0.763–2.872) 0.246
6 (2.3) 2.078 (0.787–5.486) 0.140
12 (4.6) 2.181 (1.080–4.403) 0.030*
Patients
lol (n  579)
Adjusted Hazard Ratio‡
N (%) (95% CI) p Value
86 (14.9) 0.722 (0.525–0.994) 0.046*
d Point—Secondary End Points
42 (7.3) 0.650 (0.408–1.036) 0.070
28 (4.8) 0.987 (0.587–1.660) 0.962
40 (6.9) 0.679 (0.422–1.092) 0.110
ventricular hypertrophy degree (Cornell product and Sokolow-Lyon) and baseline
es and estimates of hazard ratio of experiencing the end point on losartan comparedints i
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m Hg to 77.8 and 76.4 mm Hg in the losartan and
tenolol groups, respectively.
Also similar to the overall LIFE study, there was a larger
egression of ECG-LVH in losartan-treated African Amer-
cans compared with atenolol-treated African Americans. In
frican Americans, mean Cornell voltage-duration product
t last visit before a primary end point occurred, or at end of
ollow-up, was reduced by 193 and 79 mmms, respectively,
n the losartan and atenolol groups (p  0.056), and
okolow-Lyon voltage was reduced by 5.9 and 4.0 mm,
espectively, in the losartan and atenolol groups (p 0.018).
Distribution of study drug dosages and the use of con-
omitant medication were similar in African-American and
on-black U.S. patients; study drug discontinuation rates
ere also similar in these groups (Table 4). African-
merican and non-black U.S. patients received hydrochlo-
othiazide or another diuretic for 78% and 73% of days of
Table 3. Baseline Characteristics of Patients
All Patients
(n  9,193)
U.S.
P
(n
Age (yrs) 66.9
Female (%) 54.0
Current smoker (%) 16.3
BMI (kg/m2) 28.0
Prior CHD (%) 16.0
Prior stroke/TIA (%) 8.1
Diabetes (%) 13.0
FRS 22.4
Serum creatinine (mg/dl) 0.98
Serum glucose (mg/dl) 108.5
Serum uric acid (mg/dl) 5.6
Urine albumin (mg/dl) 6.4
Prior RAS drugs (%) 25.4
Prior BB (%) 25.9
Prior CCB (%) 25.5
Prior diuretics (%) 27.6
A t test was used to test for racial differences in continuous
was used to test for differences in dichotomous variables.
BB  beta-blocker; BMI  body mass index; CCB  c
Framingham risk score; RAS  renin angiotensin system; T
igure 2. Results of primary composite end point by ethnic group in the
.S.: blacks versus non-blacks. ttudy follow-up (through occurrence of primary end point),
espectively. In addition, an on-drug analysis of the primary
omposite end point including only those events occurring
hile patients were on study drug found a similar result to
he overall analysis favoring atenolol in black patients. The
hanges in laboratory measures in the losartan and atenolol
roups, such as serum glucose and uric acid, were similar
mong black and non-black patients.
ISCUSSION
he finding in the LIFE study that black patients seem to
ave a greater reduction in the risk of cardiovascular events
ith atenolol relative to losartan, whereas the rest of the
IFE-study participants, including the non-black U.S.
atients, benefited substantially more from losartan than
rom atenolol, is fascinating. However, there are limitations
f subanalyses, in general, and in particular the post hoc
-Black
ts
184)
U.S. Black
Patients
(n  523)
p Values
(U.S. Non-Black vs.
U.S. Black Patients)
65.0  0.001
46.5 0.036
25.0  0.001
29.5 0.066
23.1  0.001
11.1 0.435
25.4 0.007
22.2 0.006
8 1.26  0.001
117.5 0.302
6.1  0.001
16.9 0.019
36.3 0.009
21.2 0.011
48.4 0.001
38.6 0.005
es (age, FRS, and laboratory values). The Fischer exact test
channel blocker; CHD  coronary heart disease; FRS 
transient ischemic attack.
igure 3. Primary composite end point: unadjusted and adjusted for
aseline covariates in U.S. blacks (triangles) versus non-blacks (squares).
ymbols represent the hazard ratio; the line through each symbol
orresponds to the 95% confidence interval. DBP  diastolic blood
ressure; FRS  Framingham risk score; LVH  left ventricular hyper-Non
atien
 1,
67.4
52.1
13.2
28.9
32.4
9.8
19.6
23.5
1.1
115.2
5.7
12.0
43.2
27.0
36.7
31.6
variabl
alciumrophy; SBP  systolic blood pressure.
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Risk Reduction in Hypertensive Black Patients March 17, 2004:1047–55ature of the grouping of black and non-black patients, that
ust be considered. In addition, relatively few primary
ardiovascular events occurred in black patients (46 of 270
osartan-treated patients and 29 of 263 atenolol-treated
atients), which may seriously limit the stability of the
nding. It must also be recognized that it is not appropriate
Figure 4. Blood pressure results in the U.S.: blacks versus non-blacks.
Table 4. Distribution of Study Drug Dosage at T
B
Losartan
(n  26
50 mg alone 5
50 mg with additional drugs 14
With HCTZ only 8
With other drugs only 2
With HCTZ and other drugs 4
100 mg with or without additional drugs 48
Alone 0
With HCTZ only 11
With other drugs only 4
With HCTZ and other drugs 33
Off-study drug 33HCTZ  hydrochlorothiazide.o make comparisons of the individual treatments across the
lack and non-black subgroups as observed differences
ight be due to confounding factors and that there were no
djustments to the analyses for multiplicity.
Three elements led to our decision to report this obser-
ation, which might well be a chance finding. First, we
elieved that full disclosure is sound scientific practice.
econd, we hope to generate discussion in the medical
ommunity as to whether real differences exist in outcomes
etween black and non-black patients treated with the same
rug, and whether these differences can be used to guide
linical practice. Third, we firmly believe that this issue will
emain open until targeted, well-powered trials are designed
nd conducted to resolve it.
Unfortunately, the literature does not provide a complete
ramework to evaluate our findings. Contrary to the state-
ent by Schwartz (7) that “attributing differences in a
iologic endpoint to race is not only imprecise but also of no
roven value in treating an individual patient,” differences
etween ethnic groups have been documented in cardiovas-
ular research. Several cardiovascular phenotypes differ be-
ween people who are considered black and those who are
ot, although the cause of these differences may be envi-
onmental/behavioral rather than racial/genetic. Black pa-
ients with hypertension more often have low plasma renin
alues (8), appear to be more salt sensitive (8), and fit the
aragh and Sealey model of volume-expanded hypertension
9). It has been proposed that black patients are more
esponsive to treatment with diuretics or calcium antago-
ists (10). The Veterans Administration (VA) study evalu-
ting BP responsiveness to six antihypertensive drugs pro-
ided support for this concept (11), although only in elderly
lack men. This study of six antihypertensive agents was the
rst to analyze the effect of race and treatment on a
ardiovascular outcome, namely regression of LVH. Al-
hough various drugs had different effects on the regression
f End Point or End of Follow-Up
LIFE: Study Therapy
.S. Black vs. U.S. Non-Black Patients
at End Point or End of Follow-Up
n  523) Non-Black (n  1,184)
Atenolol (%)
(n  259)
Losartan (%)
(n  605)
Atenolol (%)
(n  579)
3 3 6
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9 7 9
2 4 3
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ace and outcome.
The recently reported results of the Antihypertensive
herapy and Lipid Lowering Heart Attack prevention Trial
ALLHAT) (12) reinforce the observation from the LIFE
rial that black patients with hypertension may respond
ifferently from other ethnic groups to different treatment
egimens. In the ALLHAT study, no difference was seen
etween treatment regimens (amlodipine vs. chlorthalidone
nd lisinopril vs. chlorthalidone) with respect to the primary
nd point of fatal coronary heart disease (CHD) or nonfatal
I. Black patients represented approximately 35% of the
LLHAT population. In subgroup analyses, there was no
nteraction between ethnic group and treatment with re-
pect to the primary end point. In the comparison of
isinopril to chlorthalidone, interactions between race and
reatment were observed with respect to two secondary end
oints in ALLHAT: stroke (p  0.01) and combined
ardiovascular disease (p  0.04). The hazard ratios for
isinopril relative to chlorthalidone for stroke were 1.40
95% CI 1.17 to 1.68) and 1.00 (95% CI 0.85 to 1.17) for
lack and non-black patients, respectively. The hazard
atios for combined cardiovascular disease end points were
.19 (95% CI 1.09 to 1.30) and 1.06 (95% CI 1.00 to 1.13)
or black and non-black patients, respectively. It is impor-
ant to note, however, that differences existed in BP control
n the treatment arms of the ALLHAT study. In black
atients, there was a 4 mm Hg lesser reduction in systolic
P with lisinopril in comparison to chlorthalidone. In
ddition, when comparing to the LIFE results it should be
oted that the treatment regimens were very different. First,
LLHAT did not include an angiotensin II antagonist.
econd, diuretics could not be added to the lisinopril arm in
LLHAT, whereas in the LIFE study, approximately 90%
f black patients received a diuretic at any time. Overall,
hese results do not provide definitive information with
hich to evaluate the LIFE results.
Other hypertension studies comparing effects of different
ctive agents on cardiovascular outcomes had too few black
atients to analyze separately.
Studies of the effects of ACE inhibitors and beta-blockers
n cardiovascular outcomes in patients with heart failure
eport conflicting data regarding differences in response
mong black and white patients. Analyses of data from the
wo Vasodilator-Heart Failure Trials (V-HeFT I and II)
ndicated that enalapril therapy (compared with treatment
ith a combination of hydralazine and isosorbide dinitrate)
as associated with a significant reduction in the risk of
eath from any cause among white but not among black
atients (13). Two recent reports present analyses from the
tudies Of Left Ventricular Dysfunction (SOLVD) (14,15).
ne report combining data from the Treatment and Pre-
ention arms found that enalapril therapy (compared with
lacebo) reduced the risk of hospitalization for heart failure
mong white patients with left ventricular dysfunction, but
ot among black patients. The second report analyzingrimary end point data from the Prevention arm found that
nalapril was equally efficacious in black and white patients.
oth of these reports found a higher rate of cardiovascular
utcomes in black patients relative to white patients.
In the Beta-Blocker Evaluation of Survival Trial (16) it
as found that white, but not black, patients with heart
ailure appear to benefit from the beta-blocker bucindolol.
owever, in another report (17), carvedilol reduced the risk
f death from any cause or hospitalization for any reason
and other end points) to a similar magnitude in both black
nd non-black subjects.
Thus, conflicting published data suggest, but do not
rove, the hypothesis that interruption of the renin-
ngiotensin system may be somewhat less effective in
reventing cardiovascular events in black than in non-black
ubjects. The only way we can evaluate our findings is to
iscuss, as even-handedly as possible, which aspects of our
bservations favor the conclusion that the black patients
enefited more from atenolol and which aspects militate
gainst interpreting the results in such a fashion.
The strongest argument favoring the conclusion that the
nding reported herein might represent a true and repro-
ucible difference is a statistical one. There were similar
ndings for the primary and secondary component end
oints, and a test for qualitative interaction was statistically
ignificant (p  0.016) using the Gail and Simon test,
lthough interpretation of this test must be influenced by its
ost hoc nature (6). In addition, the difference between the
roups in treatment effects on outcomes remained signifi-
ant after adjustment for a wide variety of baseline covari-
tes.
The most fascinating and perplexing observation that
peaks against accepting our findings at face value is that
osartan-based treatment had similar physiologic and hemo-
ynamic effects in black and non-black patients. As in the
verall LIFE study, for black patients, BP control through-
ut the study was similar in both treatment groups, and the
osartan-based treatment induced a larger decrease in ECG-
VH than the atenolol-based treatment. These findings
uggest that losartan-based treatment was used in appropri-
te doses and support the primary hypothesis of the LIFE
tudy, namely that the angiotensin II receptor blocking
gent losartan would antagonize the trophic effects of
ngiotensin on cardiac muscle cell hypertrophy in addition
o lowering BP in black as well as non-black patients.
In a study comparing the effects of losartan versus
tenolol treatment on vascular structure and function in
on-black patients, ex vivo evaluation of gluteal arterioles
ound treatment with losartan was associated with regres-
ion of vascular hypertrophy and improvement in endothe-
ial function, relative to atenolol, despite comparable control
f BP (18). The fact that, in the LIFE study, the regression
f ECG-LVH similarly favored losartan over atenolol in
lack patients suggests that losartan had similar antitrophic
ffects in this group.It is difficult to conceive of a mechanism whereby, in the
f
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losartan-based treatment might have some negative car-
iovascular effects in one subgroup of patients. Conversely,
here are no established mechanisms by which an atenolol-
ased treatment might have a positive effect on cardiovas-
ular outcomes only in black patients.
We diligently sought to analyze relevant factors that
ould potentially explain the differential cardiovascular out-
ome in black subjects in our study, and we were unable to
etermine a mechanism for this finding. Although we are
ully aware that there might be an unknown ethnic differ-
nce in basic physiology or in pharmacologic responses, the
act that the lesser cardiovascular protection with losartan in
lack patients is contrary to any expectation, and against the
nown physiologic frame of reference, gives reason for
aution.
Another important factor to consider in interpreting
hese data are the findings to the contrary cited in the recent
uidelines for management of hypertension in African
mericans published by the International Society on Hy-
ertension in Blacks (19). Treatment algorithms in these
uidelines recommend initiating antihypertensive therapy
ith renin aldosterone system-blocking agents in African
mericans with renal disease based on results of the African
merican Study of Kidney Disease and Hypertension
AASK) trial with the ACE inhibitor ramipril (20,21), and
n African Americans with diabetic nephropathy based on
esults of the Reduction of Endpoints in patients with
on–insulin-dependent diabetes mellitus with the Angio-
ensin II Antagonist Losartan (RENAAL) and Irbesartan
n Diabetic Nephropathy Trial (IDNT) trials with the
ngiotensin II receptor antagonists losartan and irbesartan,
espectively (22,23).
We believe that our finding is sufficiently convincing to
enerate the hypothesis that black patients with hyperten-
ion and LVH might not respond as favorably to losartan-
ased treatment as non-black patients, with respect to
ardiovascular outcomes, and that these data do not support
recommendation for losartan as a first-line treatment for
his purpose. However, this subanalysis is limited by a
elatively small number of events among black patients in
he LIFE study, and the data are insufficient to conclude
hat atenolol is superior to losartan with regard to reduction
f cardiovascular events in black patients with hypertension
nd LVH. Properly powered studies in black hypertensive
atients, in general, and in those with LVH, would be
seful to address these questions.
cknowledgments
he authors thank Bonnie Vlahos and George Klinger for
heir editorial assistance in preparation of this manuscript.
eprint requests and correspondence: Dr. Stevo Julius, Depart-
ent of Internal Medicine, Division of Hypertension, University
f Michigan Medical Center, 3918 Taubman Center, Ann Arbor,
ichigan 48109-0356. E-mail: sjulius@umich.edu.EFERENCES
1. Dahlo¨f B, Devereux RB, Kjeldsen SE, et al., for the LIFE Study
Group. Cardiovascular morbidity and mortality in the Losartan
Intervention For Endpoint reduction in hypertension study (LIFE): a
randomised trial against atenolol. Lancet 2002;359:995–1003.
2. Lindholm LH, Ibsen H, Dahlo¨f B, et al., for the LIFE Study Group.
Cardiovascular morbidity and mortality in patients with diabetes in the
Losartan Intervention For Endpoint reduction in hypertension study
(LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–
10.
3. Kjeldsen SE, Dahlo¨f B, Devereux RB, et al., for the LIFE Study
Group. Effects of losartan on cardiovascular morbidity and mortality in
patients with isolated systolic hypertension and left ventricular hyper-
trophy. A Losartan Intervention for Endpoint Reduction (LIFE)
substudy. JAMA 2002;288:1491–8.
4. Dahlo¨f B, Devereux R, de Faire U, et al., for the LIFE Study Group.
The Losartan Intervention For Endpoint reduction (LIFE) in hyper-
tension study: rationale, design, and methods. Am J Hypertens
1997;10:705–13.
5. Dahlo¨f B, Devereux RB, Julius S, et al., for the LIFE Study Group.
Characteristics of 9194 patients with left ventricular hypertrophy: the
LIFE study. Hypertension 1998;32:989–97.
6. Gail M, Simon R. Testing for qualitative interactions between
treatment effects and patient subsets. Biometrics 1985;41:361–72.
7. Schwartz RS. Racial profiling in medical research. N Engl J Med
2001;344:1392–3.
8. Luft FC, Grim CE, Weinberger MH. Electrolyte and volume ho-
meostasis in blacks. In: Hall WD, Saunders E, Shulman NB, editors.
Hypertension in Blacks: Epidemiology, Pathophysiology and Treat-
ment. Chicago, IL: Year Book Medical Publishers, 1985:115–31.
9. Laragh JH, Sealey JE. Renin system understanding for analysis and
treatment of hypertensive patients: a means to quantify the vasocon-
strictor elements, diagnose curable renal and adrenal causes, assess risk
of cardiovascular morbidity and find the best-fit drug regimen. In:
Laragh JH, Brenner BM, editors. Hypertension Pathophysiology,
Diagnosis and Management. 2nd ed. Lippincott Williams & Wilkins,
1995:1813–36.
0. Hall WD. Pharmacologic therapy of hypertension in blacks. J Clin
Hypertens 1987;3 Suppl 3:108S–13S.
1. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW,
Anderson RJ, for the VA Cooperative Study Group on Antihyperten-
sive Agents. Effect of single-drug therapy on reduction of left
ventricular mass in mild to moderate hypertension: comparison of six
antihypertensive agents. Circulation 1997;95:2007–14.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collab-
orative Research Group. Major outcomes in high-risk hypertensive
patients randomized to angiotensin-converting enzyme inhibitor or
calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-
Lowering treatment to prevent Heart Attack Trial (ALLHAT).
JAMA 2002;288:2981–97.
3. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in
response to therapy for heart failure: analysis of the Vasodilator-Heart
Failure Trials. J Card Fail 1999;5:178–87.
4. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to
angiotensin-converting enzyme inhibitor therapy in black as compared
with white patients with left ventricular dysfunction. N Engl J Med
2001;344:1351–7.
5. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of
angiotensin-converting enzyme inhibition in reducing progression
from asymptomatic left ventricular dysfunction to symptomatic heart
failure in black and white patients. J Am Coll Cardiol 2002;40:311–7.
6. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of
the beta-blocker bucindolol in patients with advanced chronic heart
failure. N Engl J Med 2001;344:1659–67.
7. Yancy CW, Fowler MB, Colucci WS, et al., for the U.S. Carvedilol
Heart Failure Study Group. Race and the response to adrenergic
blockade with carvedilol in patients with chronic heart failure. N Engl
J Med 2001;344:1358–65.
8. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of
arterial structure and endothelial dysfunction in human essential
hypertension by the angiotensin receptor antagonist losartan. Circu-
lation 2000;101:1653–9.
12
2
2
2
1055JACC Vol. 43, No. 6, 2004 Julius et al.
March 17, 2004:1047–55 Risk Reduction in Hypertensive Black Patients9. Douglas JG, Bakris GL, Epstein M, et al., for the Hypertension in
African Americans Working Group. Management of high blood
pressure in African Americans: consensus statement of the Hypertension
in African Americans Working Group of the International Society on
Hypertension in Blacks. Arch Intern Med 2003;163:525–41.
0. Agodoa LY, Appel L, Bakris GL, et al., for the African American
Study of Kidney Disease and Hypertension (AASK) Study Group. Effect
of ramipril vs amlodipine on renal outcomes in hypertensive nephroscle-
rosis: a randomized controlled trial. JAMA 2001;285:2719–28.
1. Wright JT, Bakris G, Greene T, et al., for the African American Study
of Kidney Disease and Hypertension Study Group. Effect of bloodpressure lowering and antihypertensive drug class on progression of
hypertensive kidney disease: results from the AASK trial. JAMA
2002;288:2421–31.
2. Brenner BM, Cooper ME, deZeeuw D, et al., for the RENAAL
Study Investigators. Effects of losartan on renal and cardiovascular
outcomes in patients with type 2 diabetes and nephropathy. N Engl
J Med 2001;345:861–9.
3. Parving HH, Lehnert H, Bro¨chner-Mortensen J, et al., for the Irbesartan
in Patients with Type 2 Diabetes and Microalbuminuria Study Group.
The effect of irbesartan on the development of diabetic nephropathy in
patients with type 2 diabetes. N Engl J Med 2001;345:870–8.
